Related Experiment Videos
A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia
S A MacDiarmid1, R T Emery, S F Ferguson
1Department of Urology, University of Arkansas College of Medicine and John L. McClellan Memorial Veteran's Administration Hospital, Little Rock, USA.
The Journal of Urology
|October 19, 1999
Summary
The 8 mg. dose of doxazosin showed greater efficacy than the 4 mg. dose for treating benign prostatic hyperplasia (BPH). Increasing the doxazosin dosage to 8 mg. is recommended for patients not adequately responding to 4 mg.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Doxazosin is an alpha-1 blocker used to treat BPH symptoms.
Purpose of the Study:
- To compare the efficacy of 4 mg versus 8 mg of doxazosin in patients with BPH.
- To evaluate the impact of different doxazosin dosages on symptom scores and urinary flow rates.
Main Methods:
- A double-blind study randomized 82 BPH patients already on 4 mg doxazosin to either 4 mg or 8 mg.
- Patients were assessed using the American Urological Association (AUA) symptom score, Boyarsky score, uroflowmetry, and side effect profiles at baseline, 1 month, and 3 months.
Main Results:
- The 8 mg group showed statistically significant improvements in Boyarsky scores (p <0.05) and AUA symptom scores (p <0.05) compared to the 4 mg group at 3 months.
- No significant differences were observed in maximum urinary flow rate changes between the two groups (p >0.05).
- Dropout rates and reported side effects were similar between the 4 mg and 8 mg doxazosin groups.
Conclusions:
- An 8 mg dose of doxazosin is more efficacious than 4 mg for BPH treatment.
- The 8 mg dose should be considered for patients not achieving adequate response or clinical improvement with 4 mg doxazosin, provided they tolerate the medication.